公开(公告)号：US12110308B2

公开(公告)日：2024-10-08

申请号：US16960819

申请日：2019-01-08

申请人： NUCORION PHARMACEUTICALS, INC.

发明人： Lin Zhi

IPC分类号： C07F9/6561 ,  A61K31/4162 ,  A61K31/4178 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/7052 ,  A61K31/7056 ,  A61K31/7076 ,  A61K38/21 ,  A61K45/06 ,  A61P1/16

CPC分类号： C07F9/65616 ,  A61K31/4178 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/212 ,  A61K45/06 ,  A61P1/16 ,  A61K31/4162 ,  A61K31/7052 ,  A61K31/7076

摘要： Provided herein are phosphor (n) amidatacetal and phosph (on) atacetal compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in the molecular pathways in the liver. These compounds may be effective in the treatment of hepatitis or other viral infections either alone or in combination with one or more additional therapeutic agents.

公开(公告)号：US20240285662A1

公开(公告)日：2024-08-29

申请号：US18652718

申请日：2024-05-01

申请人： Dechra Veterinary Products, LLC

发明人： Neil E. Paulsen ,  Gail L. Dempsey ,  Michael S. Daniel ,  Tiffany G. Tomlinson ,  Douglas I. Hepler ,  Raymond Petzold

IPC分类号： A61K31/7052 ,  A61K9/00 ,  A61K45/06 ,  A61K47/14 ,  A61K47/44

CPC分类号： A61K31/7052 ,  A61K9/0019 ,  A61K45/06 ,  A61K47/14 ,  A61K47/44

摘要： Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

公开(公告)号：US20240226127A1

公开(公告)日：2024-07-11

申请号：US18287722

申请日：2022-04-21

申请人： VIGONVITA LIFE SCIENCES CO., LTD.

发明人： Yang LEI ,  Gang CAO ,  Rong HU

IPC分类号： A61K31/7052 ,  A61K31/14 ,  C07H17/02

CPC分类号： A61K31/7052 ,  A61K31/14 ,  C07H17/02

摘要： The present disclosure relates to a nucleoside compound and an application thereof in the treatment of feline infectious peritonitis. The compound belongs to the GS-441524 analogues. The compound has little toxic effect on normal cat cells, while it has a significant inhibitory effect on feline coronavirus. The compound can be used to prepare feline coronavirus inhibitors for the treatment of feline infectious peritonitis. It has the advantages of good curative effect, high safety, and excellent water solubility, which makes it easier to be absorbed.

公开(公告)号：US20240180944A1

公开(公告)日：2024-06-06

申请号：US18442204

申请日：2024-02-15

申请人： LUNELLA BIOTECH, INC.

发明人： Federica SOTGIA ,  Michael P. LISANTI

IPC分类号： A61K31/7048 ,  A61K31/7052 ,  A61K45/06

CPC分类号： A61K31/7048 ,  A61K31/7052 ,  A61K45/06

摘要： This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 μM and stimulatory activity at 100 μM. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).

公开(公告)号：US20240091178A1

公开(公告)日：2024-03-21

申请号：US18520091

申请日：2023-11-27

申请人： Pulmonem Inc.

发明人： Houfar SEKHAVAT ,  Satish ASOTRA

IPC分类号： A61K31/145 ,  A61K9/00 ,  A61K9/06 ,  A61K9/14 ,  A61K31/10 ,  A61K31/65 ,  A61K31/7052 ,  A61K47/14 ,  A61K47/42 ,  A61K47/44 ,  A61M15/00 ,  A61P11/00

CPC分类号： A61K31/145 ,  A61K9/0043 ,  A61K9/0075 ,  A61K9/06 ,  A61K9/14 ,  A61K31/10 ,  A61K31/65 ,  A61K31/7052 ,  A61K47/14 ,  A61K47/42 ,  A61K47/44 ,  A61M15/0028 ,  A61M15/0065 ,  A61P11/00 ,  A61M2202/064

摘要： A method for treating patients with COVID-19 and/or other respiratory conditions includes administering eighty-five milligrams of dapsone twice daily for twenty-one days. A variety of dapsone formulations and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.

公开(公告)号：US11925657B2

公开(公告)日：2024-03-12

申请号：US18088347

申请日：2022-12-23

申请人： Sight Sciences, Inc.

发明人： Paul Badawi ,  David Y. Badawi

IPC分类号： A61K31/7052 ,  A61K9/00 ,  A61K31/194 ,  A61K31/7048 ,  A61K47/10 ,  A61P27/02 ,  A61P27/04

CPC分类号： A61K31/7052 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/194 ,  A61K31/7048 ,  A61K47/10 ,  A61P27/02 ,  A61P27/04

摘要： The present disclosure relates to methods of treating chronic conditions of the eye, such as dry eye disease and blepharitis, as well as to methods for increasing secretion of meibum. This disclosure also relates to formulations suitable for treating chronic conditions of the eye such as dry eye disease and blepharitis.

公开(公告)号：US11913959B2

公开(公告)日：2024-02-27

申请号：US17207412

申请日：2021-03-19

申请人： Memorial Sloan Kettering Cancer Center

发明人： Larry Norton ,  Ross Levine ,  Maria Kleppe ,  Elizabeth Comen

IPC分类号： C12Q1/6886 ,  G01N33/574 ,  C07K16/28 ,  A61K31/7068 ,  A61K31/7052 ,  A61K31/52 ,  A61K31/573 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/506 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  A61K31/00

CPC分类号： G01N33/57484 ,  A61K31/506 ,  A61K31/52 ,  A61K31/573 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/7068 ,  A61K38/177 ,  A61K39/3955 ,  A61K45/06 ,  C12Q1/6886 ,  G01N33/57496 ,  A61K31/00 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/7028

摘要： Provided herein are methods of treating a nonhematopoietic malignant tumor in a patient and methods of prognosing a nonhematopoietic malignant tumor in a patient, comprising administering to the patient a therapeutically effective amount of an agent that preferentially kills or inhibits proliferation or activity of leukocytes relative to nonhematopoietic cells.

公开(公告)号：US11826323B2

公开(公告)日：2023-11-28

申请号：US17955337

申请日：2022-09-28

申请人： Pulmonem Inc.

发明人： Houfar Sekhavat ,  Satish Asotra

IPC分类号： A61K31/145 ,  A61K9/00 ,  A61K9/06 ,  A61K9/14 ,  A61K31/65 ,  A61K31/7052 ,  A61K47/14 ,  A61K47/44 ,  A61P11/00 ,  A61K31/10 ,  A61K47/42 ,  A61M15/00

CPC分类号： A61K31/145 ,  A61K9/0043 ,  A61K9/0075 ,  A61K9/06 ,  A61K9/14 ,  A61K31/10 ,  A61K31/65 ,  A61K31/7052 ,  A61K47/14 ,  A61K47/42 ,  A61K47/44 ,  A61M15/0028 ,  A61M15/0065 ,  A61P11/00 ,  A61M2202/064

摘要： A method for treating patients with COVID-19 and/or other respiratory conditions includes administering eighty-five milligrams of dapsone twice daily for twenty-one days. A variety of dapsone formulations and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.

公开(公告)号：US20230372380A1

公开(公告)日：2023-11-23

申请号：US18304061

申请日：2023-04-20

申请人： Curology, Inc.

发明人： David Lortscher

IPC分类号： A61K31/7056 ,  A61K31/194 ,  A61K9/00 ,  A61K8/58 ,  A61K31/4406 ,  A61K31/455 ,  A61Q19/08 ,  A61K31/7048 ,  A61K31/20 ,  A61K31/665 ,  A61K8/55 ,  A61K8/60 ,  A61K31/315 ,  A61K8/362 ,  A61K31/555 ,  A61K31/203 ,  A61K8/49 ,  A61K8/36 ,  A61K31/7042 ,  A61K31/7052 ,  A61K31/7028

CPC分类号： A61K31/7056 ,  A61K31/194 ,  A61K9/0014 ,  A61K8/58 ,  A61K31/4406 ,  A61K31/455 ,  A61Q19/08 ,  A61K31/7048 ,  A61K31/20 ,  A61K31/665 ,  A61K8/55 ,  A61K8/602 ,  A61K31/315 ,  A61K8/362 ,  A61K31/555 ,  A61K31/203 ,  A61K8/4926 ,  A61K8/361 ,  A61K2800/59 ,  A61K31/7042 ,  A61K31/7052 ,  A61K31/7028

摘要： Pharmaceutical compositions comprising a first anti-acne compound, a second anti-acne compound, and an anti-photoaging compound are described. Methods for the treatment of acne and photoaging using the compositions are also described.

公开(公告)号：US20230330121A1

公开(公告)日：2023-10-19

申请号：US18019322

申请日：2021-08-05

申请人： Children's Hospital Medical Center

发明人： Assem Ziady ,  Kasiani Myers ,  Stella M. Davies ,  Rhonda Szczesniak ,  Emrah Gecili ,  Emily J. Skala ,  Nadeem Ayoub Ali Mousa ,  Christopher Towe ,  Laura Walkup ,  Jason Woods

IPC分类号： A61K31/7052 ,  A61K31/18 ,  A61K31/40 ,  A61K31/22 ,  A61P11/00 ,  G01N33/68

CPC分类号： A61K31/7052 ,  A61K31/18 ,  A61K31/40 ,  A61K31/22 ,  A61P11/00 ,  G01N33/6884 ,  G01N2800/12 ,  G01N2800/245 ,  G01N2800/50

摘要： Disclosed herein are compositions and methods for the treatment of bronchiolitis obliterans syndrome (BOS), in particular, in association with hematopoietic stem cell transplant (HSCT recipients, and methods for patients for effective treatment of same using protein and functional biomarkers. In certain aspect, the disclosed compositions and methods may be used for early identification of individuals likely to develop BOS such that optimal treatment may be provided, wherein the methods may employ detection and assessment of one or both of a biomarker and lung function.